BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 17659480)

  • 1. Advances in gamma-secretase modulation.
    Pissarnitski D
    Curr Opin Drug Discov Devel; 2007 Jul; 10(4):392-402. PubMed ID: 17659480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
    Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
    J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds.
    Czirr E; Weggen S
    Neurodegener Dis; 2006; 3(4-5):298-304. PubMed ID: 17047371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The structure and function of Alzheimer's gamma secretase enzyme complex.
    Krishnaswamy S; Verdile G; Groth D; Kanyenda L; Martins RN
    Crit Rev Clin Lab Sci; 2009; 46(5-6):282-301. PubMed ID: 19958215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment.
    Li T; Huang Y; Jin S; Ye L; Rong N; Yang X; Ding Y; Cheng Z; Zhang J; Wan Z; Harrison DC; Hussain I; Hall A; Lee DH; Lau LF; Matsuoka Y
    J Neurochem; 2012 Apr; 121(2):277-86. PubMed ID: 22035227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secretase inhibitors and modulators for Alzheimer's disease treatment.
    Tomita T
    Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
    D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
    Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An improved cell-based method for determining the γ-secretase enzyme activity against both Notch and APP substrates.
    McKee TD; Loureiro RM; Dumin JA; Zarayskiy V; Tate B
    J Neurosci Methods; 2013 Feb; 213(1):14-21. PubMed ID: 23219895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and mechanism of γ-secretase modulators for Alzheimer's disease.
    Crump CJ; Johnson DS; Li YM
    Biochemistry; 2013 May; 52(19):3197-216. PubMed ID: 23614767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural optimization of a CXCR2-directed antagonist that indirectly inhibits gamma-secretase and reduces Abeta.
    Bakshi P; Jin C; Broutin P; Berhane B; Reed J; Mullan M
    Bioorg Med Chem; 2009 Dec; 17(23):8102-12. PubMed ID: 19853461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. γ-Secretase modulator in Alzheimer's disease: shifting the end.
    Xia W; Wong ST; Hanlon E; Morin P
    J Alzheimers Dis; 2012; 31(4):685-96. PubMed ID: 22710916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient four-drug cocktail therapy targeting amyloid-β peptide for Alzheimer's disease.
    Asai M; Iwata N; Tomita T; Iwatsubo T; Ishiura S; Saido TC; Maruyama K
    J Neurosci Res; 2010 Dec; 88(16):3588-97. PubMed ID: 20890992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to γ-secretase modulators regardless of their potency and structure.
    Hahn S; Brüning T; Ness J; Czirr E; Baches S; Gijsen H; Korth C; Pietrzik CU; Bulic B; Weggen S
    J Neurochem; 2011 Feb; 116(3):385-95. PubMed ID: 21091478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. γ-Secretase as a target for Alzheimer's disease.
    Wolfe MS
    Adv Pharmacol; 2012; 64():127-53. PubMed ID: 22840746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abeta 11-40/42 production without gamma-secretase epsilon-site cleavage.
    Kume H; Kametani F
    Biochem Biophys Res Commun; 2006 Nov; 349(4):1356-60. PubMed ID: 16979587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Beta- and gamma-secretases].
    Iwatsubo T
    Rinsho Shinkeigaku; 2006 Nov; 46(11):925-6. PubMed ID: 17432221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of amyloid beta-peptide production by blockage of beta-secretase cleavage site of amyloid precursor protein.
    Na CH; Jeon SH; Zhang G; Olson GL; Chae CB
    J Neurochem; 2007 Jun; 101(6):1583-95. PubMed ID: 17542811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
    Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A
    J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.
    Sevalle J; Ayral E; Hernandez JF; Martinez J; Checler F
    J Neurochem; 2009 Jul; 110(1):275-83. PubMed ID: 19457123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.